CARM
Price
$0.40
Change
-$0.00 (-0.00%)
Updated
Jul 11 closing price
Capitalization
16.72M
GLUE
Price
$5.26
Change
+$0.10 (+1.94%)
Updated
Jul 14, 04:59 PM (EDT)
Capitalization
317.39M
24 days until earnings call
Interact to see
Advertisement

CARM vs GLUE

Header iconCARM vs GLUE Comparison
Open Charts CARM vs GLUEBanner chart's image
Carisma Therapeutics
Price$0.40
Change-$0.00 (-0.00%)
Volume$573.52K
Capitalization16.72M
Monte Rosa Therapeutics
Price$5.26
Change+$0.10 (+1.94%)
Volume$16.01K
Capitalization317.39M
CARM vs GLUE Comparison Chart in %
Loading...
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CARM vs. GLUE commentary
Jul 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARM is a Hold and GLUE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2025
Stock price -- (CARM: $0.40 vs. GLUE: $5.16)
Brand notoriety: CARM and GLUE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CARM: 3% vs. GLUE: 55%
Market capitalization -- CARM: $16.72M vs. GLUE: $317.39M
CARM [@Biotechnology] is valued at $16.72M. GLUE’s [@Biotechnology] market capitalization is $317.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $318.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CARM’s FA Score shows that 0 FA rating(s) are green whileGLUE’s FA Score has 1 green FA rating(s).

  • CARM’s FA Score: 0 green, 5 red.
  • GLUE’s FA Score: 1 green, 4 red.
According to our system of comparison, GLUE is a better buy in the long-term than CARM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CARM’s TA Score shows that 5 TA indicator(s) are bullish while GLUE’s TA Score has 6 bullish TA indicator(s).

  • CARM’s TA Score: 5 bullish, 5 bearish.
  • GLUE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, GLUE is a better buy in the short-term than CARM.

Price Growth

CARM (@Biotechnology) experienced а -0.74% price change this week, while GLUE (@Biotechnology) price change was +5.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +13.18%. For the same industry, the average monthly price growth was +23.65%, and the average quarterly price growth was +32.73%.

Reported Earning Dates

CARM is expected to report earnings on May 13, 2025.

GLUE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+13.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLUE($317M) has a higher market cap than CARM($16.7M). CARM YTD gains are higher at: -4.489 vs. GLUE (-25.648). GLUE has higher annual earnings (EBITDA): 6.14M vs. CARM (-49.68M). GLUE has more cash in the bank: 326M vs. CARM (7.74M). CARM has less debt than GLUE: CARM (2.33M) vs GLUE (41.9M). GLUE has higher revenues than CARM: GLUE (159M) vs CARM (20M).
CARMGLUECARM / GLUE
Capitalization16.7M317M5%
EBITDA-49.68M6.14M-809%
Gain YTD-4.489-25.64818%
P/E RatioN/A43.00-
Revenue20M159M13%
Total Cash7.74M326M2%
Total Debt2.33M41.9M6%
FUNDAMENTALS RATINGS
CARM: Fundamental Ratings
CARM
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
60
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CARMGLUE
RSI
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
89%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
86%
Advances
ODDS (%)
Bullish Trend 13 days ago
85%
Bullish Trend 6 days ago
88%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
85%
Aroon
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KLNG1.750.03
+1.74%
Koil Energy Solutions, Inc.
DNZOY13.370.06
+0.45%
Denso Corp.
CODAF7.30N/A
N/A
Codan Ltd
KISB36.00N/A
N/A
Kish Bancorp, Inc.
RPYTF155.69N/A
N/A
Reply SPA

CARM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CARM has been loosely correlated with EVGN. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if CARM jumps, then EVGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARM
1D Price
Change %
CARM100%
+0.50%
EVGN - CARM
60%
Loosely correlated
-5.52%
INSM - CARM
44%
Loosely correlated
+1.57%
PMVP - CARM
34%
Loosely correlated
-0.79%
ABCL - CARM
31%
Poorly correlated
-5.65%
VCYT - CARM
31%
Poorly correlated
-1.60%
More

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with EYPT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
-1.90%
EYPT - GLUE
48%
Loosely correlated
-6.33%
ATXS - GLUE
44%
Loosely correlated
-4.50%
IMNM - GLUE
43%
Loosely correlated
-3.46%
CRSP - GLUE
43%
Loosely correlated
-3.73%
DNLI - GLUE
43%
Loosely correlated
-5.41%
More